nebulized levofloxacin — Competitive Intelligence Brief

nebulized levofloxacin (nebulized levofloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluoroquinolone antibiotic. Area: Infectious diseases.

phase 3 fluoroquinolone antibiotic DNA gyrase and topoisomerase IV Infectious diseases Small molecule

Target snapshot

nebulized levofloxacin (nebulized levofloxacin) — University of Rochester. Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nebulized levofloxacin TARGET	nebulized levofloxacin	University of Rochester	phase 3	fluoroquinolone antibiotic	DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Third generation fluoroquinolone	Third generation fluoroquinolone	University of Roma La Sapienza	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
levofloxacin-based triple therapy	levofloxacin-based triple therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (in combination therapy)	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% eye drops	moxifloxacin 0.5% eye drops	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin HCl 0.5%	Moxifloxacin HCl 0.5%	Carolina Eyecare Physicians, LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fluoroquinolone antibiotic class)

1. Allergan · 1 drug in this class
2. Shenzhen Third People's Hospital · 1 drug in this class
3. Sun Yat-sen University · 1 drug in this class
4. University of Rochester · 1 drug in this class